Anavex Life Sciences (AVXL) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Compass Therapeutics (CMPX) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 79.8% versus a loss of 85.4%. Over five years, CMPX leads with a -73.5% price change compared with -92.7% for AVXL. Compass Therapeutics is the larger company by market cap ($154.9 million vs $121.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | CMPX |
|---|---|---|
| Share price | $1.31 | $0.86 |
| Market cap | $121.43M | $154.88M |
| 1-day change | -11.49% | -4.09% |
| YTD return | -63.20% | -83.99% |
| 1-year return | -85.41% | -79.81% |
| 5-year return | -92.66% | -73.54% |
| EPS (TTM) | $-0.14 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-46.38M | $-66.49M |
| 52-week high | $9.50 | $6.88 |
| 52-week low | $1.30 | $0.822 |
| Distance from 52-week high | -86.21% | -87.50% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +533.72% |
| Average volume | 1.01M | 4.30M |
| Shares outstanding | 92.70M | 180.09M |
| Employees | 34 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Healthcare · Biotechnology · 34 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
AVXL vs CMPX FAQ
Which is bigger, Anavex Life Sciences or Compass Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $154.88M compared with $121.43M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, AVXL or CMPX?
CMPX returned -79.81% over the past 12 months, compared with -85.41% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.